Spots Global Cancer Trial Database for fallopian tube adenocarcinoma

Every month we try and update this database with for fallopian tube adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	NCT03641287	Ovarian Cancer Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton...	Exercise Counse... Aerobic Exercis... Physiological S... Quality-of-Life... Questionnaire A... Best Practice	18 Years -	University of Washington
FT516 and IL2 With Enoblituzumab for Ovarian Cancer	NCT04630769	Ovarian Cancer Fallopian Tube ... Primary Periton...	IP FT516 Enoblituzumab IL-2	18 Years -	Masonic Cancer Center, University of Minnesota
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	NCT03641287	Ovarian Cancer Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton...	Exercise Counse... Aerobic Exercis... Physiological S... Quality-of-Life... Questionnaire A... Best Practice	18 Years -	University of Washington
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma	NCT03608618	Peritoneal Meso... Fallopian Tube ... Adenocarcinoma ... Primary Periton...	MCY-M11 Cyclophosphamid...	18 Years -	MaxCyte, Inc.
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy	NCT03593681	Fallopian Tube ... Ovarian Cancer Ovarian Neoplas... Ovary Cancer Fallopian Tube ... Fallopian Tube ... High Grade Sero... Peritoneal Carc... Peritoneal Neop... Adnexal Mass Ovarian Disease...	Hysteroscopic c...	18 Years -	Boston Scientific Corporation
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02923739	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Emactuzumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
FT516 and IL2 With Enoblituzumab for Ovarian Cancer	NCT04630769	Ovarian Cancer Fallopian Tube ... Primary Periton...	IP FT516 Enoblituzumab IL-2	18 Years -	Masonic Cancer Center, University of Minnesota
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery	NCT04498117	Carcinoma, Ovar... Ovarian Neoplas... Ovarian Cancer Ovarian Serous ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... Peritoneal Carc... Peritoneal Neop...	Oregovomab Paclitaxel Carboplatin Placebo Carboplatin	18 Years -	CanariaBio Inc.
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	NCT02834013	Acinar Cell Car... Adenoid Cystic ... Adrenal Cortica... Adrenal Gland P... Anal Canal Neur... Anal Canal Undi... Angiosarcoma Apocrine Neopla... Appendix Mucino... Bartholin Gland... Basal Cell Carc... Bladder Adenoca... Breast Metaplas... Cervical Adenoc... Cholangiocarcin... Chordoma Colorectal Squa... Desmoid Fibroma... Endometrial Tra... Endometrioid Ad... Esophageal Neur... Esophageal Undi... Extrahepatic Bi... Extramammary Pa... Fallopian Tube ... Fallopian Tube ... Fibromyxoid Tum... Gallbladder Car... Gastric Neuroen... Gastric Squamou... Gastric Undiffe... Gastrointestina... Gestational Tro... Giant Cell Carc... Human Papilloma... Intestinal Neur... Intrahepatic Ch... Lung Neuroendoc... Lung Sarcomatoi... Major Salivary ... Malignant Odont... Malignant Perip... Malignant Solid... Malignant Testi... Metastatic Mali... Metastatic Pitu... Minimally Invas... Mixed Mesoderma... Mucinous Adenoc... Mucinous Cystad... Nasal Cavity Ad... Nasal Cavity Ca... Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Oral Cavity Car... Oropharyngeal U... Ovarian Adenoca... Ovarian Germ Ce... Ovarian Mucinou... Ovarian Squamou... Ovarian Transit... Pancreatic Acin... Pancreatic Neur... Paraganglioma Paranasal Sinus... Paranasal Sinus... Parathyroid Gla... PEComa Penile Squamous... Peritoneal Meso... Placental Chori... Primary Periton... Pseudomyxoma Pe... Rare Disorder Scrotal Squamou... Seminal Vesicle... Seminoma Serous Cystaden... Small Intestina... Small Intestina... Spindle Cell Ne... Teratoma With S... Testicular Non-... Thyroid Gland C... Tracheal Carcin... Transitional Ce... Ureter Adenocar... Ureter Squamous... Urethral Adenoc... Urethral Squamo... Vaginal Adenoca... Vaginal Squamou... Vulvar Carcinom...	Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02923739	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Emactuzumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy	NCT00899093	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Ovarian Adenoca... Primary Periton... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Undifferentiate... Undifferentiate...	Cytology Specim... Laboratory Biom...	18 Years -	GOG Foundation
Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma	NCT02217956	Ovarian Adenoca... Fallopian Tube ... Primary Periton...	Cisplatin Bevacizumab	18 Years - 65 Years	Gustave Roussy, Cancer Campus, Grand Paris
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy	NCT03593681	Fallopian Tube ... Ovarian Cancer Ovarian Neoplas... Ovary Cancer Fallopian Tube ... Fallopian Tube ... High Grade Sero... Peritoneal Carc... Peritoneal Neop... Adnexal Mass Ovarian Disease...	Hysteroscopic c...	18 Years -	Boston Scientific Corporation
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	NCT02020707	Cervical Adenoc... Cervical Adenos... Cervical Adenos... Cervical Carcin... Cervical Squamo... Clinical Stage ... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Und... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Femal... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Perit... Malignant Solid... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian High Gr... Ovarian Mucinou... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Unresectable Me... Uterine Corpus ...	Bevacizumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: